Literature DB >> 1849157

Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

W L Drew1, R C Miner, D F Busch, S E Follansbee, J Gullett, S G Mehalko, S M Gordon, W F Owen, T R Matthews, W C Buhles.   

Abstract

Seventy-two AIDS patients treated with ganciclovir for cytomegalovirus (CMV) disease were prospectively monitored for the development of drug-resistant virus. No resistant strains were found in 31 patients before therapy or among seven culture-positive patients treated for less than or equal to 3 months. Of 13 culture-positive patients treated for greater than or equal to 3 months, 5 excreted virus resistant (ED50, greater than 12 microM, or ED90, greater than 30 microM) to ganciclovir. Thus, 38% of patients and receiving ganciclovir for greater than 3 months and excreting virus or, overall, 7.6% of the patients were excreting CMV resistant to the drug.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849157     DOI: 10.1093/infdis/163.4.716

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  67 in total

Review 1.  Changing patterns of HIV related ocular disease.

Authors:  S Rauz; P I Murray
Journal:  Sex Transm Infect       Date:  1999-02       Impact factor: 3.519

2.  A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Authors:  M L Landry; S Stanat; K Biron; D Brambilla; W Britt; J Jokela; S Chou; W L Drew; A Erice; B Gilliam; N Lurain; J Manischewitz; R Miner; M Nokta; P Reichelderfer; S Spector; A Weinberg; B Yen-Lieberman; C Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Rapid determination of human cytomegalovirus susceptibility to ganciclovir directly from clinical specimen primocultures.

Authors:  J M Pepin; F Simon; A Dussault; G Collin; M C Dazza; F Brun-Vezinet
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

4.  Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.

Authors:  R Snoeck; G Andrei; D Schols; J Balzarini; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

Review 5.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

6.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

Review 7.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 8.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

9.  Drug-resistant herpesviruses: should we look for them?

Authors:  G Boivin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

Review 10.  Management of CMV retinitis in HIV infected patients.

Authors:  C Katlama
Journal:  Genitourin Med       Date:  1997-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.